This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
ATLANTA, May 26, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its first quarter 2010 financial results will be released after the market close on Thursday, June 3, and will be followed by an investor conference call on the same day at 4:30 p.m. ET.
The conference call will be hosted by Dan Myers, President and Chief Executive Officer, and Rick Eiswirth, Chief Financial Officer.
To participate in the call, please dial (877) 369-6586 (USA) or (253) 237-1165 (International). To access the live webcast, please visit the Investor Relations section on the corporate web site at
A replay of the conference call will be available beginning June 3, 2010 at 7:30 p.m. ET and ending on July 3, 2010 by dialing (800) 642-1687 (USA) or (706) 645-9291 (International), Conference ID Number: 76977260. A replay of the webcast will also be available on the corporate website for one month, through July 3, 2010.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate Iluvien® is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
CONTACT: ICR, LLC
For Alimera Sciences